a onesizefits-all vaccine that showed promise at preventing pancreatic cancer from coming back. The new clinical trial results were published yesterday. Pancreatic cancer we know is a major concern because its 5-year survival rate is only about 13% and up to 80% of those cancers have a high potential to come back.NBC News medical contributor Dr. . Natalie Azar is here to break down the results of this trial for us. And I feel like the word game changer was made for this this sort of a a story.We know that t ...

Vaccine Recommendations & Insurance Coverage - Removing recommendations may impact patient choice, especially for vulnerable populations who rely on no-cost vaccines linked to CDC and ASIP recommendations [1][3] - Insurance companies have individual policies, some may not cover important treatments [2] - Various programs (private insurers, employer-sponsored plans, Medicare Part D, Medicaid, Vaccines for Children) link no-cost vaccines to CDC/ASIP recommendations [3] FDA's Role & Vaccine Safety - FDA's role is to assess the safety and effectiveness of submitted applications [4] - Concerns raised about potential loss of trust in the FDA due to policies perceived as "rubber stamping" vaccines without sufficient evidence, particularly for young, healthy individuals [5] - Industry emphasizes the need for strong evidence when recommending interventions, especially for new viruses and vaccines [5] - Clinical trial results in children were mixed four years ago [6]